This Article Figures Only Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jenkins, J R Search for Related Content PubMed PubMed Citation Articles by Jenkins, J R

A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons)

School of Clinical Sciences, Division of Gastroenterology, University of Liverpool, Henry Wellcome Laboratory, Crown Street, Liverpool L69 3BX, UK

Correspondence: John Roland Jenkins, School of Clinical Sciences, Division of Gastroenterology, University of Liverpool, Henry Wellcome Laboratory, Crown Street, Liverpool L69 3BX, UK. E-mail: John.Jenkins{at}liverpool.ac.uk

Topoisomerase II poisons are an established part of best clinical practice for the treatment of a number of solid tumours and haematological malignancies. However, toxicity and resistance to chemotherapeutic drugs often complicate the treatment. Furthermore, topoisomerase II poisons can also induce sister chromatid exchange, chromosomal recombination and chromosome aberrations and are associated with a significant risk of secondary leukaemia. It would therefore be of great clinical benefit if the efficacy of topoisomerase II inhibitors could be enhanced without the increased toxic side effects. It is proposed that clinical agents targeting topoisomerase II can be enhanced by inhibiting proteins that modulate topoisomerase II. The aim is to identify proteins, that by the nature of their interaction with topoisomerase II, represent putative drug targets.